Balyasny Asset Management

Balyasny Asset Management (BAM) is a diversified global investment firm and hedge fund founded in 2001. It manages over $25 billion in assets and operates more than 20 offices worldwide. The firm specializes in multi-strategy investing across equities long/short, fixed income & macro, commodities, multi‐asset arbitrage, and systematic strategies. BAM’s mission centers on delivering absolute returns uncorrelated to broader markets through proprietary research and collaborative teams[1][4][5].

While BAM invests across many sectors—including healthcare and life sciences—it does not itself develop drugs or therapeutic platforms.

Notable for its entrepreneurial culture and focus on talent development, the company has weathered industry challenges (notably a difficult period in 2018) by adapting its approach[3]. Key leadership includes founder Dmitry Balyasny (Managing Partner & CIO), Taylor O’Malley (Co-Founder & President), and Scott Schroeder (Co-Founder)[1][2].

The company has participated as an investor in some health-related ventures but does not operate as a biotech/pharma/CRO/CMO/platform company.

As of June 2025: - Assets under management exceed $25 billion[4][5] - Over 2,000 employees globally[5] - Headquarters are located in Chicago with additional offices across North America, Europe, Middle East & Asia[4][5]

No clinical pipeline or drug development activities are associated with the firm.

Revenue estimates vary; one source lists approximately $515 million annually[10].